Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.53 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9230108 | 0.89 | RAB9A (0.56) | NPC1ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL11390139 | 0.88 | ALDH1A1 (0.58) | NPC1ALDH1A1TSHRKMT2APOLB | |
| SCHEMBL28945385 | 0.88 | ALDH1A1 (0.53) | NPC1ALDH1A1KMT2AMEN1POLB | |
| Trifluoroacetic Acid SCHEMBL5153804 | 0.88 | PDK1 (0.53) | NPC1ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL10778839 | 0.87 | SMN1; SMN2 (0.52) | NPC1TSHRKMT2APOLBHTT | |
| Hydrochloric Acid SCHEMBL11405284 | 0.84 | SMN1; SMN2 (0.50) | NPC1TSHRKMT2APOLBHTT | |
| SCHEMBL11048619 | 0.82 | MEN1 (0.76) | NPC1ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL21568080 | 0.82 | NPC1 (0.67) | NPC1ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL4741253 | 0.82 | MEN1 (0.76) | NPC1ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL3423025 | 0.82 | PDK1 (0.55) | NPC1KMT2ARAB9ASMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11326018-B2 | Process for the synthesis of polyoxazolidinone compounds | COVESTRO DEUTSCHLAND AG (DE) | 2022-05-10 | — | — | US | claimed |
| US-11319398-B2 | Method for the production of polyoxazolidinone polymer compounds | COVESTRO DEUTSCHLAND AG (DE) | 2022-05-03 | — | — | US | claimed |
| EP-3630717-B1 | A PROCESS FOR THE SYNTHESIS OF AROMATIC CARBAMATES | COUNCIL SCIENT IND RES (IN) | 2022-02-09 | — | — | EP | claimed |
| EP-3577149-B1 | METHOD FOR THE PRODUCTION OF POLYOXAZOLIDINONE POLYMER COMPOUNDS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2022-02-09 | — | — | EP | claimed |
| US-20210284785-A1 | PROCESS FOR THE SYNTHESIS OF POLYOXAZOLIDINONE COMPOUNDS | COVESTRO DEUTSCHLAND AG (DE) | 2021-09-16 | — | — | US | claimed |
| US-20210253528-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | claimed |
| EP-3500611-B1 | PROCESS FOR THE SYNTHESIS OF POLYOXAZOLIDINONE COMPOUNDS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2021-08-11 | — | — | EP | claimed |
| CN-109642010-B | Synthesis method of polyoxazolidone compound | 科思创德国股份有限公司 | 2021-06-04 | — | — | CN | claimed |
| EP-3820843-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-05-19 | — | — | EP | claimed |
| US-20210130527-A1 | METHOD FOR THE PRODUCTION OF POLYOXAZOLIDINONE POLYMER COMPOUNDS | COVESTRO DEUTSCHLAND AG (DE) | 2021-05-06 | — | — | US | claimed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | claimed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | claimed |
| EP-0820281-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING N-CHLOROPHENYLCARBAMATES AND N-CHLOROPHENYLTHIOCARBAMATES FOR INHIBITING THE GROWTH OF VIRUSES AND CANCERS | THE PROCTER & GAMBLE COMPANY (US) | 1998-01-28 | — | — | EP | claimed |
| JP-2598819-B2 | — | — | 1997-04-09 | — | — | JP | claimed |
| WO-1996032104-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING N-CHLOROPHENYLCARBAMATES AND N-CHLOROPHENYLTHIOCARBAMATES FOR INHIBITING THE GROWTH OF VIRUSES AND CANCERS | THE PROCTER & GAMBLE COMPANY (US) | 1996-10-17 | — | — | WO | claimed |
| EP-0340243-B1 | CC-1065 ANALOGS | UPJOHN CO (US) | 1994-09-28 | — | — | EP | claimed |
| EP-0340243-A1 | CC-1065 ANALOGS. | UPJOHN CO (US) | 1989-11-08 | — | — | EP | claimed |
| WO-1988004659-A2 | NOVEL CC-1065 ANALOGS | THE UPJOHN COMPANY (US) | 1988-06-30 | — | — | WO | claimed |
| US-4453969-A | Thienylglyoxylonitrile oximino phenylcarbamates for the protection of crops against injury by herbicides | CIBA-GEIGY CORPORATION (US) | 1984-06-12 | — | — | US | claimed |
| US-4453974-A | TREATMENT OF SEEDS OR SEEDLINGS | CIBA-GEIGY CORPORATION (US) | 1984-06-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253528-A1 | CHEMICAL COMPOUNDS | ATF4, EIF2AK4, ATF1 | NPC1 62/4885ALDH1A1 3644/4885TSHR 2906/4885 |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | NPC1 4728/4885ALDH1A1 515/4885TSHR 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.